Prevalence of monoclonal gammopathy of undetermined significance in an elderly urban Korean population

American Journal of Hematology

Volumn 86, Issue 9, 2011, Pages 752-755

  Park, Hyun Kyung ^a   Lee, Kyoung Ryul ^a   Kim, Young Jin ^a   Cho, Han Ik ^a   Eun Kim, Jung ^b   Woong Kim, Ki ^b   Jung Kim, Yu ^b   Lee, Keun Wook ^b   Hyun Kim, Jee ^b   Bang, Soo Mee ^b   Lee, Jong Seok ^b  

^a Seoul Medical Science Institute   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BLOOD SAMPLING; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FREE LIGHT CHAIN; HUMAN; KOREA; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; URBAN POPULATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD SEDIMENTATION; COHORT STUDIES; COMPLEMENT FIXATION TESTS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH SURVEYS; HUMANS; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; PREVALENCE; REPUBLIC OF KOREA; RISK FACTORS; SEX CHARACTERISTICS; URBAN HEALTH;

EID: 80051781732     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22095     Document Type: Article

References (23)

1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
4. Kim SJ, Kim K, Kim BS, et al. Clinical features and survival outcomes in patients with multiple myeloma: Analysis of web-based data from the Korean Myeloma Registry. Acta Haematol 2009; 122: 200-210.
5. Kyle RA. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med 1978; 64: 814-826.
6. Singh J, Dudley AW Jr, Kulig KA. Increased incidence of monoclonal gammopathy of undetermined significance in blacks and its age-related differences with whites on the basis of a study of 397 men and one woman in a hospital setting. J Lab Clin Med 1990; 116: 785-789.
7. Cohen HJ, Crawford J, Rao MK, et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998; 104: 439-444.
8. Iwanaga M, Tagawa M, Tsukasaki K, et al. Prevalence of monoclonal gammopathy of undetermined significance: Study of 52, 802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007; 82: 1474-1479.
9. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007; 82: 1468-1473.
10. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006; 107: 904-906.
11. Park JH, Lim S, Lim J, et al. An overview of the Korean longitudinal study on health and aging. Psychiatry Invest 2007; 4: 84-95.
12. Drayson M, Tang LX, Drew R, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902.
13. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812-817.
14. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-1444.
15. Cha YJ, Paik NH, Park AJ. Incidence of M-components in 9813 sera. Korean J Lab Med 1987; 7: 191-196.
16. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 1362-1369.
17. Lee JH, Bang SM. Epidemiological change of multiple myeloma in Korea. Korean J Hematol 2006; 41: 225-234.
18. Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231-239.
19. Katzmann JA, Abraham RS, Dispenzieri A, et al. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005; 51: 878-881.
20. Piehler AP, Gulbrandsen N, Kierulf P, Urdal P. Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population. Clin Chem 2008; 54: 1823-1830.
21. Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc 2006; 81: 1575-1578.
22. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for detection of monoclonal gammopathies. Clin Chem 2009; 55: 1517-1522.
23. Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: A retrospective population-based cohort study. Lancet 2010; 375: 1721-1728.